Stephen Lynch, MD
Interventional Cardiology · Southfield, MINPI 1396128187
Payments from drug & device makers
Across 194 payments — averaging $103.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Circulation Inc$7K
- Amgen$2K
- Abbott$1K
- Edwards Lifesciences$1K
- Ancora Heart, Inc.$1K
- Inari Medical, Inc.$1K
- plus $6K from 28 others
Across 1 payment — averaging $220.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Circulation Inc$220
What the payments were for
- Consulting fees$1,8009%
- Speaking & faculty fees$1,1256%
- Travel & lodging$4,89424%
- Food & beverage$11,53358%
- Education$6333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Circulation Inc | 16 | $6,911 |
| Amgen | 24 | $1,906 |
| Abbott | 17 | $1,410 |
| Edwards Lifesciences | 12 | $1,410 |
| Ancora Heart, Inc. | 5 | $1,201 |
| Inari Medical, Inc. | 23 | $1,069 |
| Abiomed | 7 | $836 |
| Boston Scientific | 6 | $630 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $536 |
| Novartis | 7 | $449 |
| Cathworks, Inc. | 2 | $437 |
| E.r. Squibb & Sons, L.L.C. | 13 | $355 |
| AstraZeneca | 5 | $324 |
| Stryker | 8 | $290 |
| Penumbra, Inc. | 2 | $277 |
| Inquis Medical, Inc. | 2 | $270 |
| Philips North America LLC | 2 | $232 |
| Astellas Pharma US Inc | 2 | $198 |
| Johnson & Johnson | 2 | $198 |
| Kestra Medical Technology Services, Inc. | 2 | $154 |
| Shockwave Medical, Inc | 1 | $153 |
| Sanofi | 1 | $150 |
| Chiesi USA, Inc. | 5 | $136 |
| Medtronic | 3 | $114 |
| Novo Nordisk | 1 | $105 |
| Pfizer | 3 | $56 |
| Teleflex LLC | 2 | $36 |
| Impulse Dynamics (USA) Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $28 |
| Merck | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TherOx DS2 Console$6,646
- Catheter$6,646
- Downstream Cartridge$6,646
- Repatha$1,321
- AccuCinch$1,064
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,036
- FLOWTRIEVER CATHETER, S$730
- CT THROMBECTOMY SYSTEM KIT$474
- FFRangio$437
- Impella$408
- ENTRESTO$374
- Penumbra System$277
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$154
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$153
- Aventus$151
- FABRAZYME$150
- CARDIOMEMS$148
- AVVIGO Guidance System$146
- PERCLOSE PROGLIDE$137
- OPTIS$137
How this compares
$19,985 in reported general payments places this provider in the 60th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $135,481 |
| EntrestoSacubitril/Valsartan | 50 | $59,896 |
| JardianceEmpagliflozin | 25 | $36,219 |
| XareltoRivaroxaban | 22 | $21,593 |
| Repatha SureclickEvolocumab | 18 | $14,430 |
| Metoprolol Succinate | 181 | $3,750 |
| Ranolazine ErRanolazine | 15 | $2,325 |
| ClopidogrelClopidogrel Bisulfate | 105 | $2,001 |
| Atorvastatin Calcium | 104 | $1,521 |
| Losartan Potassium | 105 | $1,513 |
| Rosuvastatin Calcium | 93 | $1,240 |
| Carvedilol | 82 | $1,152 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $1,083 |
| Bumetanide | 21 | $785 |
| Amlodipine Besylate | 80 | $663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $135,481107 claims |
| NovartisEntresto | $449 | $59,89650 claims |
| Boehringer IngelheimJardiance | $28 | $36,21925 claims |
| Johnson & JohnsonXarelto | $198 | $21,59322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Southfield
- Shukri DavidSouthfield$1.6M
- Marcel ZughaibSouthfield$1.2M
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Qaiser ShafiqSouthgate$1.3M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
- Harry ColferPetoskey$940K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.